Prospective cohort study of respiratory effects at ages 14 to 26 following early life exposure to arsenic in drinking water

Md Alfazal Khan, Meera Hira-Smith, Syed Imran Ahmed, Mohammad Yunus, S. M. Tafsir Hasan, Jane Liaw, John Balmes, Rubhana Raqib, Yan Yuan, David Kalman, Taehyun Roh, Craig Steinmaus, Allan H. Smith

Background: We previously reported chronic respiratory effects in children who were then 7–17 years of age in Matlab, Bangladesh. One group of children had been exposed to high concentrations of arsenic in drinking water in utero and early childhood (average 436 µg/L), and the other group of children were never known to have been exposed to >10 µg/L. The exposed children, both males and females, had marked increases in chronic respiratory symptoms. Methods: The current study involves a further follow-up of these children now 14–26 years of age with 463 located and agreeing to participate. They were interviewed for respiratory symptoms and lung function was measured. Data were collected on smoking, body mass index (BMI), and number of rooms in the house as a measure of socioeconomic status. Results: Respiratory effects were still present in males but not females. In the high exposure group (>400 µg/L in early life) the odds ratio (OR) among male participants for dry cough in the last 12 months was 2.36 (95% confidence interval [CI] = 1.21, 4.63, P = 0.006) and for asthma OR = 2.51 (95% CI = 1.19, 5.29, P = 0.008). Forced vital capacity (FVC) was reduced in males in the early life high-exposure group compared with those never exposed (<95ml, P = 0.04), but not in female participants. Conclusions: By the age range 14–26, there was little remaining evidence of chronic respiratory effects in females but pronounced effects persisted in males. Mechanisms for the marked male female differences warrant further investigation along with further follow-up to see if respiratory effects continue in males.

Keywords: Arsenic; Lung function; Respiratory; Pulmonary; In utero; Children; Early life exposure

Introduction

Arsenic in drinking water has been linked to various nonmalignant respiratory illnesses. Several studies in adults have suggested an increased risk of respiratory symptoms and diseases including impairment of lung function following chronic exposure to inorganic arsenic. Long-term exposure to inorganic arsenic has been found to be associated with increased risk of respiratory symptoms such as chronic cough, dyspnea and breathlessness and the relationships were dose-dependent. A cross-sectional study in Bangladesh found a greater risk of chronic bronchitis with added sounds in chest among people having arsenic-induced skin lesions compared with people without these lesions. Excess mortality from nonmalignant lung disease has been reported recently for the same cohort with the highest exposure group having a 75% increased risk of mortality compared with the lowest exposure group. Several studies have also observed declines in lung function following exposure to arsenic via drinking water.

There is growing evidence that early life arsenic exposure has profound health effects in later life. Arsenic readily crosses the placenta in human beings. Exposure to arsenic in utero and early childhood resulted in increased mortality among young adults 30–49 years of age from lung cancer and bronchiectasis in Chile. For those born during the high arsenic exposure period 1958–1970, the standardized mortality ratios (SMRs) for lung cancer and bronchiectasis were 6.1 (95% confidence interval [CI] = 3.5, 9.9; P < 0.001) and 46.2 (95% CI = 21.1,

What this study adds

This prospective study involves children who had been exposed to high concentrations of inorganic arsenic in drinking water in utero and early life. We previously assessed them at 7–17 years of age and found increased chronic respiratory symptoms. In this article, we report our findings when they were 14–26 years of age in what is the first study to assess adolescents and young adults following early life exposure to arsenic. Pronounced respiratory effects were still present in males but had largely disappeared in females. Mechanisms for the marked male female differences warrant further investigation.
87.7, P < 0.001), respectively. A recent study in Chile revealed increased incidence of lung cancer following arsenic exposure and the association was strongest in younger adults exposed to arsenic in early life. Lung cancer is considered the major long-term cause of death following exposure to arsenic in drinking water. Exposure to arsenic in prenatal life and early childhood via drinking water in Chile was also found to be associated with reduced lung function in a study following early life arsenic exposure. A study following in utero arsenic exposure in Bangladesh found evidence of reduced lung function and airway inflammation at age 9, mainly in boys. While there is considerable evidence that early life arsenic exposure increases lung disease in adults, only limited information is available on pulmonary effects in children themselves before adulthood. A study in Antofagasta, Chile, in the 1970s reported reduction in prevalence of respiratory symptoms in children after reduction in water arsenic concentrations. In utero and early life exposure to arsenic has also been found to be associated with increased risk of respiratory infections in infants. Few studies have investigated arsenic exposure during fetal development and early life on respiratory consequences in infants and children. Evidence suggested that early life arsenic exposure resulted in long-term nonmalignant pulmonary diseases in adults and much later in life as indicated by increased mortality from bronchiectasis and lung cancer, in adults. So far, no study has followed children with well-documented early life arsenic exposure to assess long-term health consequences in the later part of childhood and as young adults. We were the first to follow a cohort with high arsenic exposure in early life and assess respiratory and other health effects in children, then 7–17 years of age. We now further assess these same children at 14–26 years of age.

Methods

Since 1966, the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) has been maintaining an internationally recognized and unique Health and Demographic Surveillance System (HDSS) in 142 villages in Matlab, a Subdistrict of Bangladesh. Vital events including birth, death, marriage, and in and out migration, are recorded by household visits every 2 months. In 2002–2003, icddr,b conducted a population-based survey of all 220,000 Matlab residents, documenting the residential tubewell history of each individual over the age of 5 at the time. Tubewells near residences were the main source of drinking water in these communities. Moreover, arsenic measurements were conducted in 2002–2003 for all 13,286 tubewells in operation in the Matlab area. In our first study of early life arsenic exposure in this population, 650 potential participants born between 1991 and 2002 were selected using the population survey database of 220,000 residents in the subdistrict of Matlab. Half of them were selected because they had the highest recorded tubewell water arsenic concentrations in the homes where they were born, and the other half were selected because they had the lowest tubewell arsenic concentrations in the homes where they were born.

In the earlier study, we were able to locate and obtain maternal exposure data during pregnancy and assess respiratory symptoms for 571 of the 650 when they were in the age range 7–17, and they constitute the target for this follow-up study. We visited the households of potential participants for the follow-up. We found that 27 were known to have moved out of the Matlab district, 17 declined to participate, and 64 could not be located and we have no information about them. In the end, in total 463 participants were included in the current follow-up study when they were in the age range of 14–26 (Figure 1). Of them, 235 and 228 children participated in the exposed and unexposed cohorts, respectively. Among the 235 exposed children, 135 were in the high exposure (400–µg/L) group, and 100 in the medium exposure (10–400 µg/L) group. The questionnaires were revised to record information of the new houses, schools, and work places and their water sources, and also new water sources of the previous homes and the schools.

Assessment of respiratory and other medical illnesses

Detailed histories of respiratory symptoms and disorders including wheezing, asthma, pneumonia, and tuberculosis since our last visit between 2008 and 2010 were taken. Ever and current wheezing (i.e., wheezing in the last 12 months), and asthma were assessed based on the core questionnaire of the international Study of Asthma and Allergy in Childhood (ISAAC), a validated tool used for the assessment of asthma symptoms in children worldwide. Cough and phlegm, shortness of breath, and family history of asthma were obtained according to an ISAAC supplementary questionnaire; http://links.lww.com/EE/A76. Two trained physicians asked the questions in a structured interview.

Anthropometric and lung function measurement

Height and weight were obtained for all participants before testing lung function. Standing height was measured to the nearest of 0.1 cm and weight was measured using a bathroom scale to the nearest of 100 gm. Lung function was measured with the EasyOne spirometer (NDD Medical Technologies) which has been used successfully in many studies including our previous one with the same children in Bangladesh. It is a handy, portable spirometer that uses ultrasound to measure airflow. The measurement is independent of gas composition, pressure, temperature, and humidity, and eliminates errors due to those variables making it suitable for the hot and humid conditions in Matlab. After explaining the procedure and demonstrating it, subjects were asked to blow out forcibly as hard as possible through the disposable mouthpiece in the standing position without using a nose clip. The procedure was repeated on average four times in order to produce smooth, reproducible curves that meet American Thoracic Society criteria. Spirometry was conducted by a physician with extensive experience administering spirometry on children. Lung function parameters, primarily forced vital capacity (FVC), FEV1 (forced expiratory volume in first second), and FEV1/FVC ratio, were recorded. Spirometry measurements were obtained for 463 participants without use of bronchodilators. The quality was excellent with grade A being achieved for 95% (440 participants) and grade B for 5% (23 participants). No tests were graded C–F. All the spirometry results were used in the analysis. In addition, lung function data were reviewed by our pulmonologist co-investigator (Professor John Balmes).

Because of the gender differences we found with respiratory effects now confined to males, we identified gender difference reported in other studies of respiratory effects associated with exposure to inorganic arsenic in water above 50 µg/L. We also assessed gender differences in published studies of arsenic-caused skin lesions, since this is a useful marker of the effects of exposure to arsenic in drinking water. Finally, we identified studies of arsenic methylation as a potential explanation of the gender differences. Inorganic arsenic is first mono-methylated to monomethylarsonic acid (MMA) the trivalent form which is highly toxic, and one possibility was that the preponderance of some arsenic effects in males could be due to more arsenic remaining as MMA in males compared with females, and not being further methylated to less toxic dimethylarsinic acid (DMA).

Ethical considerations

The institutional review boards of the University of California, Berkeley and icddr,b approved the study. Informed consent was
obtained from parents and young adults over 18 years of age and assent was obtained from children 14–17 of age.

**Data analysis**

Univariate analyses were conducted to evaluate the differences in general characteristics and socio-demographic factors between the low and high exposed cohorts. We performed Fisher’s exact test to compare the dichotomous respiratory symptoms between the cohorts separated by sex. Logistic regression analysis was used to assess the relationship of each respiratory symptom with arsenic water concentrations initially adjusting for age and gender, and then for each gender separately. Children exposed to >400 µg/L in early life (high exposure) and 10–400 µg/L in early life (medium exposure) were compared with children exposed to <10 µg/L in early life (low exposure). Because of the pronounced gender differences found, results are presented for each gender separately. Variables adjusted for were age, body mass index (BMI), smoking (self and father), and number of rooms in the house. No female participants or mothers reported smoking. Multiple linear regression analysis was used to assess the association of water arsenic concentration with FEV1 and FVC. First, age, sex, and height were included in the linear regression model. Then more analyses were conducted adjusted for age, height, weight, smoking (self and father), and number of rooms in the house. In view of the clear direction of the hypothesis that there might be increased risks of respiratory effects associated with exposure to arsenic in drinking water, P-values reported are one-tailed. All CIs are 95%.

**Results**

A total of 463 subjects 14–26 years of age participated in this study. The mean age was 18.1 years. Table 1 presents socio-demographic characteristics of the study subjects. Among the participants, 135 (29.2%) were exposed to high arsenic concentrations in early life (>400 µg/L), 100 (21.6%) were exposed to medium arsenic concentrations (10–400 µg/L) and 228 (48.2%) were exposed to low concentration of As (<10µg/L). Of the total 463 subjects, 229 (49.5%) were males and 234 (50.5%) were females. Participants below the age of 17 years were more likely to have been exposed to high arsenic concentration compared with the 22–26 years age group (46.7% vs. 14.1%). Participants with more educated fathers were found to have used lower arsenic concentration water in early life. The proportion of fathers who smoked was about the same in the low exposure participants compared with those highly exposed (61.8% compared with 62.2%). Respondents residing in higher quality type houses had similar exposure patterns as those in low quality mud houses. The number of rooms in the house as an indicator of socioeconomic status also had a little relationship with exposure. Other factors including BMI and respondent’s educational status were similar across the exposure groups.

Odds ratios (ORs) for respiratory symptoms are shown in Table 2 for males and in Table 3 for females. After adjustment for age, BMI, self, and father’s smoking status and rooms in the house, the OR for dry cough in the last 12 months in males in the high exposure cohort was increased (OR: 2.36, 95% CI = 1.21–4.63, P = 0.006). Other symptoms for highly exposed males were also markedly increased including woken up with shortness of breath (OR: 1.71, 95% CI = 0.90, 3.24, P = 0.05) and shortness of breath when walking on level ground (OR: 2.21, 95% CI = 0.86, 5.67, P = 0.05). Asthma was also markedly increased in highly exposed males (OR: 2.51, 95% CI = 1.19, 5.29, P = 0.008). There were 86 male participants who reported smoking, but the respiratory symptom findings were similar for smokers and nonsmokers (see Supplementary material; http://links.lww.com/EE/A76). Thus, there was no evidence of synergy of arsenic exposure with smoking.

However, increased respiratory symptoms with arsenic exposure were not found in females. and in fact for many respiratory symptoms the odds ratios among females were <1 in the highly exposed group (Table 3).

Table 4 presents lung function test results analyzed by multiple linear regression. It displays the differences in two major pulmonary function parameters, FEV1 and FVC between the highly exposed group (>400 µg/L) and the medium exposed group (10–400 µg/L), compared with the low exposure cohort with <10 µg/L of arsenic in early life drinking water. We adjusted for age, height, weight, self and father’s smoking status, and rooms in the house. The results showed decreased FEV1 in
males in the high exposure group compared with those exposed to <10 µg/L (−75 mL, 95% CI = −180.1, 30.2, \(P = 0.08\)) and FVC (−95 mL, 95% CI = −201.1, −11.0, \(P = 0.04\)). However, there was no reduction in the two lung function parameters in exposed females.

Table 5 presents key findings we identified in published studies giving gender specific data on arsenic effects. There were gender differences for all five studies of chronic respiratory effects and six studies of arsenic-cause skin lesions with males showing greater effects. Finally, many studies now show that men do not metabolize arsenic as well as women. This is reflected in higher concentrations of highly toxic MMA in men compared with women as seen in the studies listed in Table 5.

Discussion

To our knowledge, this is the first study that has followed a cohort exposed to arsenic in early life to investigate the effects of in utero and early childhood exposure on respiratory effects in adolescents and young adults. Males with early life arsenic exposure (>400 µg/L) were more likely to report various respiratory symptoms including dry cough, woken up due to shortness of breath and asthma. Reductions in FEV1 and FVC were observed in male subjects with high arsenic exposure compared with low arsenic exposure. However, these effects were not evident in females.

Long-term exposure to arsenic via drinking water has been implicated with chronic respiratory illnesses in several studies in adults.7–10,17 A prospective study in Bangladesh showed an inverse dose–response relationship between arsenic and lung function parameters, FEV1, and FVC. Individuals in the highest baseline water arsenic category (>97 µg/L) had a significant reduction in FEV1 and FVC of 80.6 and 97.3 mL, respectively.13 A study in India reported increased respiratory symptoms including impairment in lung function among those with long-term exposure to arsenic in drinking water and the effects were more pronounced in males compared with females. Men with arsenic induced skin lesions had a 256 mL (95% CI = 114, 398.4; \(P < 0.001\)) and 288 mL (95% CI = 134.9, 440.8; \(P < 0.001\)) reduction in FEV1 and FVC, respectively.1 Findings from a study in Chile suggested that prenatal exposure to arsenic increases the risk of respiratory illnesses later in life.21 A recent

Table 1. Socio-demographic characteristics of study participants (total n = 463)

| Characteristics | Total N (%) | <10 µg/L; N (%) | 10–400 µg/L; N (%) | >400 µg/L; N (%) | \(P^a\) |
|-----------------|-------------|----------------|-------------------|-----------------|------|
| Sex             |             |                |                   |                 |      |
| Male            | 229 (49.5)  | 108 (47.4)     | 47 (47.0)         | 74 (54.8)       | 0.17 |
| Female          | 234 (50.5)  | 120 (52.6)     | 53 (53.0)         | 61 (45.2)       |      |
| Age (years)     |             |                |                   |                 |      |
| 14–17           | 224 (48.4)  | 118 (51.8)     | 43 (43.0)         | 63 (46.7)       | 0.39 |
| 18–21           | 163 (35.2)  | 74 (32.5)      | 36 (36.0)         | 53 (39.3)       |      |
| 22–26           | 76 (16.4)   | 36 (15.8)      | 21 (21.0)         | 19 (14.1)       |      |
| BMI             |             |                |                   |                 |      |
| <18             | 150 (32.4)  | 76 (33.3)      | 29 (29.0)         | 45 (33.3)       | 0.71 |
| ≥18             | 313 (67.6)  | 152 (66.7)     | 71 (71.0)         | 90 (66.7)       |      |
| Education (years) |       |                |                   |                 |      |
| No              | 3 (0.7)     | 2 (0.9)        | 1 (1.0)           | 0 (0.0)         | 0.24 |
| 1–5             | 54 (11.7)   | 20 (8.8)       | 9 (9.0)           | 25 (18.5)       |      |
| 6–10            | 302 (65.2)  | 151 (66.2)     | 66 (66.0)         | 85 (63.0)       |      |
| 11–15           | 100 (21.6)  | 53 (23.3)      | 23 (23.0)         | 24 (17.8)       |      |
| 16+             | 4 (0.9)     | 2 (0.9)        | 1 (1.0)           | 1 (0.7)         |      |
| Smoking         |             |                |                   |                 |      |
| Yes             | 86 (18.6)   | 35 (15.4)      | 21 (21.0)         | 30 (22.2)       | 0.21 |
| No              | 377 (81.4)  | 193 (84.7)     | 79 (79.0)         | 105 (77.8)      |      |
| No. of family members | |functions parameters in exposed females.

Table 5 presents key findings we identified in published studies giving gender specific data on arsenic effects. There were gender differences for all five studies of chronic respiratory effects and six studies of arsenic-cause skin lesions with males showing greater effects. Finally, many studies now show that men do not metabolize arsenic as well as women. This is reflected in higher concentrations of highly toxic MMA in men compared with women as seen in the studies listed in Table 5.

Discussion

To our knowledge, this is the first study that has followed a cohort exposed to arsenic in early life to investigate the effects of in utero and early childhood exposure on respiratory effects in adolescents and young adults. Males with early life arsenic exposure (>400 µg/L) were more likely to report various respiratory symptoms including dry cough, woken up due to shortness of breath and asthma. Reductions in FEV1 and FVC were observed in male subjects with high arsenic exposure compared with low arsenic exposure. However, these effects were not evident in females.

Long-term exposure to arsenic via drinking water has been implicated with chronic respiratory illnesses in several studies in adults.7–10,17 A prospective study in Bangladesh showed an inverse dose–response relationship between arsenic and lung function parameters, FEV1, and FVC. Individuals in the highest baseline water arsenic category (>97 µg/L) had a significant reduction in FEV1 and FVC of 80.6 and 97.3 mL, respectively.13 A study in India reported increased respiratory symptoms including impairment in lung function among those with long-term exposure to arsenic in drinking water and the effects were more pronounced in males compared with females. Men with arsenic induced skin lesions had a 256 mL (95% CI = 114, 398.4; \(P < 0.001\)) and 288 mL (95% CI = 134.9, 440.8; \(P < 0.001\)) reduction in FEV1 and FVC, respectively.1 Findings from a study in Chile suggested that prenatal exposure to arsenic increases the risk of respiratory illnesses later in life.21 A recent
study in Mexico has reported reduction in FVC in children following exposure to arsenic in utero and early childhood. Actually, we do not know of any study with enough participants having arsenic water concentrations above 50 µg/L that has not found chronic respiratory effects.

In our previous study of the same cohorts in Bangladesh at 7–17 years of age, we found strong associations between chronic respiratory symptoms, especially wheezing when not having a cold (OR = 8.41, 95% CI = 1.66, 42.6), and shortness of breath when walking fast or climbing (OR = 3.19, 95% CI = 1.22, 8.32), with prenatal exposure to arsenic of >500 µg/L in drinking water, but there was little effect on lung function. Respiratory symptom effects at that time were evident for both boys and girls.

However, the present study found elevated risks of respiratory symptoms only among males while there was now no

### Table 2.

| Respiratory symptoms                          | <10 µg/L  | 10–400 µg/L | >400 µg/L |
|-----------------------------------------------|-----------|-------------|-----------|
|                                              | N OR 95% CI | P*         | N OR 95% CI | P*         |
| Coughing                                      |           |             |           |
| When having a cold (last 12 months)           | 76        | 0.57 0.27, 1.22 | 0.93 48 | 0.70 0.36, 1.35 | 0.86 |
| When not having a cold (last 12 months)       | 17        | 0.47 0.15, 1.50 | 0.90 11 | 0.90 0.39, 2.09 | 0.59 |
| Dry cough (last 12 months)                    | 24        | 1.49 0.67, 3.31 | 0.16 29 | 2.36 1.21, 4.63 | 0.006 |
| Wheezing                                      |           |             |           |
| Ever                                          |           |             |           |
| Last 12 months                                | 37        | 20 1.33 0.65, 2.72 | 0.22 34 | 1.60 0.86, 2.95 | 0.07 |
| Number of wheezing attacks (1–3 times)        | 6         | 4 1.40 0.37, 5.32 | 0.31 8 | 2.07 0.67, 6.37 | 0.10 |
| Number of wheezing attacks (4+ times)         | 3         | 0           |           |
| Number of nights sleep disturbed (<1/week)    | 1         | 1 2.28 0.14, 3.86 | 0.28 6 | 11.6 1.30, 103 | 0.01 |
| Number of nights sleep disturbed (1 or more/week) | 3       | 1 0.56 0.05, 6.01 | 0.68 2 | 0.80 0.12, 5.37 | 0.59 |
| Severe enough to affect speech                 | 6         | 3 1.07 0.25, 4.60 | 0.46 8 | 1.99 0.65, 6.14 | 0.12 |
| Without exercise                              | 1         | 1 2.78 0.16, 4.87 | 0.24 3 | 4.32 0.43, 43.9 | 0.11 |
| When having a cold                            | 7         | 2 0.60 0.12, 3.05 | 0.73 9 | 1.96 0.68, 5.65 | 0.11 |
| When not having a cold                        | 3         | 2 1.37 0.22, 8.66 | 0.37 5 | 2.28 0.52, 10.0 | 0.14 |
| Shortness of breath                           |           |             |           |
| Woken up with shortness of breath             | 31        | 17 1.25 0.59, 2.63 | 0.28 33 | 1.71 0.90, 3.24 | 0.05 |
| Woken up with tightness of chest              | 12        | 8 1.39 0.51, 3.78 | 0.26 12 | 1.38 0.57, 3.36 | 0.24 |
| When walking fast or climbing                 | 25        | 9 0.66 0.27, 1.53 | 0.84 26 | 1.58 0.81, 3.17 | 0.09 |
| When walking on level ground                  | 9         | 6 1.61 0.53, 4.93 | 0.20 12 | 2.21 0.86, 5.67 | 0.05 |
| Asthma                                        | 16        | 12 1.80 0.75, 4.27 | 0.09 23 | 2.51 1.19, 5.29 | 0.008 |

*Adjusted for age, BMI, smoking (self and father), and number of rooms in house.

*One-tailed P-value.

### Table 3.

| Respiratory symptoms                          | <10 µg/L  | 10–400 µg/L | >400 µg/L |
|-----------------------------------------------|-----------|-------------|-----------|
|                                              | N OR 95% CI | P*         | N OR 95% CI | P*         |
| Coughing                                      |           |             |           |
| When having a cold (last 12 months)           | 71        | 34 1.37 0.69, 2.74 | 0.19 33 | 0.83 0.45, 1.59 | 0.72 |
| When not having a cold (last 12 months)       | 15        | 5 0.74 0.25, 2.22 | 0.70 7 | 0.91 0.35, 2.39 | 0.57 |
| Dry cough (last 12 months)                    | 63        | 30 1.13 0.57, 2.22 | 0.36 31 | 0.96 0.51, 1.79 | 0.56 |
| Wheezing                                      |           |             |           |
| Ever                                          |           |             |           |
| Last 12 months                                | 28        | 18 1.57 0.74, 3.33 | 0.12 19 | 1.44 0.70, 2.93 | 0.16 |
| Number of wheezing attacks (1–3 times)        | 10        | 4 0.87 0.25, 3.07 | 0.58 2 | 0.35 0.07, 1.69 | 0.90 |
| Number of wheezing attacks (4+ times)         | 3         | 1 0.69 0.06, 8.27 | 0.61 1 | 0.55 0.05, 5.79 | 0.69 |
| Number of nights sleep disturbed (<1/week)    | 2         | 3 3.64 0.54, 24.6 | 0.09 0 |
| Number of nights sleep disturbed (1 or more/week) | 7       | 1 0.29 0.03, 2.51 | 0.87 4 | 1.04 0.29, 3.76 | 0.48 |
| Severe enough to affect speech                 | 6         | 3 1.06 0.24, 4.63 | 0.47 3 | 0.94 0.23, 3.95 | 0.53 |
| After exercise                                | 12        | 5 0.93 0.30, 2.94 | 0.55 4 | 0.60 0.18, 1.98 | 0.80 |
| Without exercise                              | 3         | 1 0.32 0.03, 3.68 | 0.82 1 | 0.43 0.04, 4.75 | 0.75 |
| When having a cold                            | 10        | 5 1.14 0.35, 3.70 | 0.41 4 | 0.74 0.22, 2.50 | 0.69 |
| When not having a cold                        | 1         | 0           |           |
| Shortness of breath                           |           |             |           |
| Woken up with shortness of breath             | 18        | 14 2.18 0.94, 5.05 | 0.04 13 | 1.49 0.66, 3.37 | 0.17 |
| Woken up with tightness of chest              | 12        | 11 2.05 0.78, 5.37 | 0.07 10 | 1.75 0.69, 4.44 | 0.12 |
| When walking fast or climbing                 | 49        | 24 1.04 0.53, 2.06 | 0.45 26 | 1.04 0.51, 2.05 | 0.46 |
| When walking on level ground                  | 22        | 11 1.23 0.53, 2.85 | 0.32 11 | 0.99 0.44, 2.22 | 0.51 |
| Asthma                                        | 22        | 11 1.07 0.45, 2.52 | 0.44 12 | 1.04 0.46, 2.33 | 0.46 |

*Adjusted for age, BMI, smoking (self and father), and number of rooms in house.

*One-tailed P-value.
effect of early life arsenic exposure among females. Interestingly, we observed reduced lung function among the male participants which was absent in the cohort study when they were younger. Although these sex specific findings are somewhat surprising, many studies have reported gender differences in arsenic effects. Key studies and findings are presented concerning gender differences in Table 5. Pesola et al found the risk for dyspnea was greater among males compared with females. Parvez et al observed that arsenic exposure affected FEV1 only in men and the risk for reduced FVC was greater among males. Similarly, von Ehrenstein et al found increased respiratory symptoms in India and a marked decline in both FVC and FEV1 in arsenic exposed males, but not in females. Dauphine et al showed that early life arsenic exposure in Chile had a detrimental effect on lung function, especially FVC in adult males. Raqib et al found that the correlation between prenatal inorganic arsenic and acute respiratory infections was stronger in boys in comparison to girls.

Gender variation has also been observed in arsenic-induced skin lesions with higher risks among males (Table 5). A study in Mexico reported that boys living in an arsenic-contaminated area scored poorly on various cognitive tests in

| Study | Health effect | Population studied | Key finding regarding gender differences |
|-------|---------------|-------------------|----------------------------------------|
| Parvez et al, 2013 | Bangladesh | Greater reduction in FEV1 (male = −66.6; female= −29.3) and FVC (male= −63.9; female= −46.0) in males |
| Pesola et al, 2012 | Bangladesh | Dyspnea crude OP male = 2.01 (1.15, 3.52); P = 0.019; female = 1.51 (1.24, 1.85; P < 0.001) |
| Dauphine et al, 2011 | Chile | Much greater reductions in FEV1 (male = −440; female = −17) and FVC (male = −673; female = −27) in males |
| Raqib et al, 2009 | Bangladesh | Acute respiratory infections in boys 6–12 months: r = 0.57, P = 0.02; girls: r = 0.07, P = 0.86 (at gestation weeks 6–10) |
| von Ehrenstein et al, 2005 | India | Shortness of breath OR for male nonsmokers with no skin lesions = 3.8 (95% CI = 0.7, 20.6), for female nonsmokers with no skin lesions = 1.6 (0.6, 4.2) |
| Lindberg et al, 2008 | Bangladesh | Male OR for skin lesions compared with females 1.3 (95% CI = 1.0, 1.7) |
| Ahsan et al, 2006 | Bangladesh | Male adjusted 1.8 (P = 0.03) prevalence odds ratio 4.15 (95% CI = 3.27, 5.26) compared with females |
| Rahman et al, 2006 | Bangladesh | Males had a higher risk of obtaining skin lesions than females (odds ratio 10.9 vs. 5.78) in the highest average exposure quintile (P = 0.005) |
| von Ehrenstein et al, 2005 | India | 50.4% of study source population was female, but skin lesions male: n = 93; female: n = 39 |
| Kadono et al, 2002 | Bangladesh | Skin lesions overall more severe in males (P < 0.001); each type also more severe in males (keratosis on soles P < 0.001; keratosis on palms P < 0.05; melanosis and hypopigmentation on trunk P < 0.05) |
| Guha Mazumder et al, 1998 | India | Keratosis prevalence per 100: male = 3.0; female = 1.2; Hyperpigmentation prevalence per 100: male = 6.4; female = 3.1 |
| Wei et al, 2018 | China | Male %MMA = 15.92 (SD 4.71); female %MMA = 13.62 (SD 4.16) |
| Lindberg et al, 2008 | Bangladesh | Males over 20 associated with higher %MMA (Beta coefficient −0.36, P < 0.01) in multiple regression analysis |
| Lindberg et al, 2007 | Hungary, Romania, Slovakia | Males correlated with higher %MMA (Beta coefficient −0.14, P < 0.01) in multiple regression analysis |
| Steinmaus et al, 2006 | Argentina and USA | Women had lower %MMA in both Argentina and US (Women: Argentina = 13.4%; US = 10.4%. Men: Argentina = 14.8%; US = 13.9%) |
| Gambie et al, 2005 | Bangladesh | Women %MMA at 11.5 ± 4.8 vs 15.5 ± 5.2 in men |
| Hsieh et al, 2003 | Taiwan | Males %MMA = 16.5 ± 1.1; females = 13.6 ± 0.8; P < 0.05 |
| Chen et al, 2003 | Taiwan | Men had lower methylation efficiency in both steps of methylation. For the secondary step DMA(V) / MMA(V), men = 10.02 (SD13.66); women = 11.71 (SD 12.85); P = 0.32 |
| Loffredo et al, 2003 | Chile, China, Mexico | In the Mexico, high exposure group MMA concentrations were higher in men (158.4) than women (133.7). Numbers of participants from the other countries were too few to assess |
| Hsieh et al, 1998 | Taiwan | Males %MMA = 20.23 ± 1.13; females = 13.89 ± 0.88; P < 0.05 |
| Hopenhayn-Rich et al, 1996 | Chile | Women had lower %MMA. At about 600 µg/L, women = 12.8 (3.7–25.7) and men = 16.5 (7.0–26.8) |
| Hopenhayn-Rich et al, 1996 | Chile | For subjects exposed to either about 15 µg/L or about 600 µg/L (low and high exposure groups combined), mean %MMA for women = 11.5 (SD 4.3) and men = 14.4 (SD5.9) |
comparison to girls living in the same area. Differences in arsenic effects between males and females may be due to sex differences in arsenic metabolism (Table 5). Males are reported to have lower methylation capacity than females, so more arsenic is present in inorganic form or as MMA3, both of which are highly toxic. Although one might expect stronger findings in males than in females, we have no explanation for the sex-specific findings in this follow-up compared with our first study. It seems that the respiratory symptom effects in girls have largely disappeared, while boys continue to have symptoms and now also have evidence of reduced lung function. Further follow-up of these children, including urinary arsenic speciation, may help elucidate these puzzling observations.

The mechanisms by which arsenic causes chronic respiratory illness via drinking water are not well understood. Immune suppression is considered one of the possible ways. A review of published reports suggests that arsenic causes immune suppression by inducing apoptosis, oxidative stress, and inflammation. Early life arsenic exposure through drinking water has been found to be associated with reduced size and function of the thymus leading to immune suppression and increased susceptibility to infection. In vitro evidence suggests that arsenic alters the respiratory epithelial barrier and impairs wound repair through the upregulation of MMP-9 by pulmonary epithelial cells.

One of the strengths of the current study is the individual assessment of drinking water arsenic exposure levels during prenatal life, and individual arsenic exposure assessment in childhood. A limitation of the study was that we did not take water samples from tube well sources that were used for < 6 months; which might affect exposure status to some extent. A more important limitation was that we are not able to separate effects of exposure in utero from exposure in early childhood. The reason for this is that the drinking water the mother used during pregnancy was mostly the same water as used by the child after birth. We therefore refer to “early life exposure” and not to “in utero” exposure in the title and elsewhere in the article. Another limitation was not having urine concentrations during pregnancy in addition to the water arsenic concentrations. However, with the wide distribution of water arsenic concentrations with a major contrast between high and low exposure, not having urine concentrations is not important. In addition, urine concentrations only measure arsenic exposure spanning a few days. We were surprised that there is now no evidence of respiratory effects in girls. This suggests that with reductions in arsenic exposure, girls may recover from respiratory effects more rapidly than boys. Further follow-up of our cohort will show if respiratory effects persist in males and if females have permanently recovered from chronic respiratory effects resulting from early life exposure. We conclude by noting that there is extensive evidence that there are long-term effects resulting from early life exposure to arsenic so every effort should be made to reduce exposure especially in early life.

Conflicts of interest

The authors declare that they have no conflicts of interest with regard to the content of this report.

Acknowledgments

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and University of California, Berkeley, acknowledge with gratitude the commitment of US National Institutes of Health (NIH) for its research efforts. icddr,b is also grateful to the Governments of Bangladesh, Canada, Sweden, and the United Kingdom for providing core/unrestricted support. The authors are gratefully indebted to all participants of the present study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.

References

1. von Ehrenstein OS, Mazumder DN, Yuan Y, et al. Decrements in lung function related to arsenic in drinking water in West Bengal, India. Am J Epidemiol. 2005;162:533–541.
2. Mazumder DN, Haque R, Ghosh N, et al. Arsenic in drinking water and the prevalence of respiratory effects in West Bengal, India. Int J Epidemiol. 2000;29:1047–1052.
3. Mazumder DN, Steinmaus C, Bhattacharyya P, et al. Bronchiectasis in persons with skin lesions resulting from arsenic in drinking water. Epidemiology. 2005;16:136–140.
4. Milton AH, Rahman M. Respiratory effects and arsenic contaminated well water in Bangladesh. Int J Environ Health Res. 2002;12:175–179.
5. Smith AH, Marshall G, Yuan Y, Liaw J, Ferreccio C, Steinmaus C. Evidence from Chile that arsenic in drinking water may increase mortality from pulmonary tuberculosis. Am J Epidemiol. 2011;173:414–420.
6. Guo X, Fujino Y, Chai J, et al. The prevalence of subjective symptoms after exposure to arsenic in drinking water in Inner Mongolia, China. J Epidemiol. 2003;13:211–215.
7. Parvez F, Chen Y, Brandt-Rauf PW, et al. A prospective study of respiratory symptoms associated with chronic arsenic exposure in Bangladesh: findings from the Health Effects of Arsenic Longitudinal Study (HEALS). Thorax. 2010;65:528–533.
8. Pesola GR, Parvez F, Chen Y, Ahmed A, Hasan R, Ahsan H. Arsenic exposure from drinking water and dyspnrea risk in Araihazar, Bangladesh: a population-based study. Eur Respir J. 2012;39:1076–1083.
9. Guo X, Yuan Y, Liaw J, Ferreccio C, Steinmaus C. Arsenic exposure from drinking water and dyspnrea risk in Araihazar, Bangladesh: a population-based study. Eur Respir J. 2012;39:1076–1083.
10. Ghosh P, Banerjee M, De Chaudhuri S, et al. Comparison of health effects between individuals with and without skin lesions in the population exposed to arsenic through drinking water in West Bengal, India. J Expo Sci Environ Epidemiol. 2007;17:215–223.
11. Paul S, Das N, Bhattacharjee P, et al. Arsenic-induced toxicity and carcinogenicity: a two-wave cross-sectional study in arsenicosis individuals in West Bengal, India. J Expo Sci Environ Epidemiol. 2013;23:156–162.
12. Milton AH, Hasan Z, Rahman A, Rahman M. Chronic arsenic poisoning and respiratory effects in Bangladesh. Journal of Occupational Health. 2001;43:136–140.
13. Argos M, Parvez F, Rahman M, et al. Arsenic and lung disease mortality in Bangladesh adults. Epidemiology. 2014;25:536–543.
14. Parvez F, Chen Y, Yunus M, et al. Arsenic exposure and impaired lung function. Findings from a large population-based prospective cohort study. Am J Respir Crit Care Med. 2013;188:813–819.
15. Staaf AA, Kazzi A, Fatmi Z, Irfan M, Ali A, Kayama F. Lung function decrement with arsenic exposure to drinking groundwater along River Indus: a comparative cross-sectional study. Environ Geochem Health. 2011;33:203–216.
16. De BK, Majumdar D, Sen S, Guru S, Kundu S. Pulmonary involvement in chronic arsenic poisoning from drinking contaminated ground-water. J Assoc Physicians India. 1997;45:382–385.
17. Concha G, Vogler G, Lezcano D, Nermell B, Vahter M. Exposure to inorganic arsenic metabolites during early human development. Toxicol Sci. 1998;44:185–190.
18. Smith AH, Marshall G, Yuan Y, et al. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ Health Perspect. 2006;114:1293–1296.
19. Steinmaus C, Ferreccio C, Acvedo J, et al. Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. Cancer Epidemiol Biomarkers Prev. 2014;23:1529–1538.
20. Smith AH, Goycoola M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol. 1998;147:660–669.
21. Yuan Y, Marshall G, Ferreccio C, et al. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am J Epidemiol. 2007;166:1381–1391.
22. Daunphiné DC, Ferreccio C, Guntur S, et al. Lung function in adults following in utero and childhood exposure to arsenic in drinking water: preliminary findings. Int Arch Occup Environ Health. 2011;84:591–600.
23. Ahmad S, Akhtar E, Roy A, et al. Arsenic exposure alters lung function and airway inflammation in children: a cohort study in rural Bangladesh. Environ Int. 2017;101:108–116.
24. Zaldivar R, Ghat GL. Clinical epidemiological studies on endemic chronic arsenic poisoning in children and adults, including observations on children with high- and low-intake of dietary arsenic. Zentralbl Bakteriol. 1980;170:409–421.
24. Rahman A, Vahter M, Ekstrom EC, Persson LÅ. Arsenic exposure in pregnancy increases the risk of lower respiratory tract infection and diarrhea during infancy in Bangladesh. Environ Health Perspect. 2011;119:719–724.

25. Raqi B, Ahmed S, Sultana R, et al. Effects of in utero arsenic exposure on child immunity and morbidity in rural Bangladesh. Toxicol Lett. 2009;185:197–202.

26. Steinmaus C, Ferreccio C, Acevedo J, et al. High risks of lung disease associated with early-life and moderate lifetime arsenic exposure in northern Chile. Toxicol Appl Pharmacol. 2016;313:10–15.

27. Vahter M. Health effects of early life exposure to arsenic. Basic Clin Pharmacol Toxicol. 2008;102:204–211.

28. Smith AH, Yunus M, Khan AF, et al. Chronic respiratory symptoms in children following in utero and early life exposure to arsenic in drinking water in Bangladesh. Int J Epidemiol. 2013;42:1077–1086.

29. Asher MI, Weiland SK. The International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC steering committee. Clin Exp Allergy. 1998;28(suppl 5):52–66; discussion 90-1.

30. Shaw R, Woodman K, Ayson M, et al. Measuring the prevalence of bronchial hyper-responsiveness in children. Int J Epidemiol. 1995;24:597–602.

31. Weiland SK, Bjorksten B, Brunekreef B, Cookson WO, von Mutius E, Strachan DP. International Study of Asthma and Allergies in Childhood Phase II Study Group. Phase II of the International Study of Asthma and Allergies in Childhood (ISAAC II): rationale and methods. Eur Respir J. 2004;24:406–412.

32. American Thoracic Society: Standardization of Spirometry, 1994 update: American Thoracic Society. Am J Respir Crit Care Med. 1995;152:1107–1136.

33. Lindberg AL, Rahman M, Persson LA, Vahter M. The risk of arsenic induced skin lesions in Bangladesh men and women is affected by arsenic metabolism and the age at first exposure. Toxicol Appl Pharmacol. 2008;230:9–16.

34. Ahson H, Chen Y, Parvez F, et al. Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the Health Effects of Arsenic Longitudinal Study. Am J Epidemiol. 2006;163:1138–1148.

35. Rahman M, Vahter M, Sohel N, et al. Arsenic exposure and age and sex-specific risk for skin lesions: a population-based case-referent study in Bangladesh. Environ Health Perspect. 2006;114:1847–1852.

36. Kadono T, Inaoka T, Murayama N, et al. Skin manifestations of arsenicism in two villages in Bangladesh. Int J Dermatol. 2002;41:841–846.

37. Guha Mazumder DN, Haque R, Ghosh N, et al. Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. Int J Epidemiol. 1998;27:871–877.

38. Wei B, Yu J, Li H, et al. Arsenic metabolites and methylation capacity among individuals living in a rural area with endemic arseniasis in Inner Mongolia, China. Biol Trace Elem Res. 2016;170:300–308.

39. Lindberg AL, Ekstrom EC, Nermell B, et al. Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh. Environ Res. 2008;106:110–120.

40. Lindberg AL, Kumar R, Goessler W, et al. Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ Health Perspect. 2007;115:1081–1086.

41. Steinmaus C, Bates MN, Yuan Y, et al. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J Occup Environ Med. 2006;48:478–488.

42. Gamble MV, Lu X, Ahsan H, et al. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. Environ Health Perspect. 2005;113:1683–1688.

43. Hsueh YM, Ko YF, Huang YK, et al. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol Lett. 2003;137:49–63.

44. Chen YC, Guo YL, Lu HJ, et al. Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med. 2003;45:241–248.

45. Loffredo CA, Aposhian HV, Cebran ME, Yamauchi H, Silbergeld EK. Variability in human metabolism of arsenic. Environ Res. 2003;92:85–91.

46. Hsueh YM, Huang CC, Hsu-Min Chen WLW, Yang MH, Lu LC, Chen CJ. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health. 1999;54(part A):431–444.

47. Hopenhayn-Rich C, Biggs ML, Kalman DA, SMITH AH. Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Water Environ Health Perspect. 1996;104:1200–1207.

48. Hopenhayn-Rich C, Biggs ML, SMITH AH, Kalman DA, SMITH LE. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect. 1996;104:620–628.

49. Recio-Vega R, Gonzalez-Cortes T, Olivas-Caldron E, Lantz RC, Gandolfi AJ, Gonzalez-De Alba C. In utero and early childhood exposure to arsenic decreases lung function in children. J Appl Toxicol. 2015;35:338–366.

50. Sanchez TR, Perzanowski M, Graziano JH. Inorganic arsenic and respiratory health, from early life exposure to sex-specific effects: a systematic review. Environ Res. 2016;147:537–555.

51. Rosado JL, Ronquillo D, Kordas K, et al. Arsenic exposure and cognitive performance in Mexican schoolchildren. Environ Health Perspect. 2007;115:1371–1375.

52. Vahter M, Akeson A, Lidén C, Ceccatelli S, Berglund M. Gender differences in the disposition and toxicity of metals. Environ Res. 2007;104:85–95.

53. de la Fuente H, Portales-Perez D, Baranda L, et al. Effect of arsenic, cadmium, and lead on the induction of apoptosis of normal human mononuclear cells. Clin Exp Immunol. 2002;129:69–77.

54. Rocha-Amador DO, Calderón J, Carrizales L, Costilla-Salazar R, Pérez-Maldonado IN. Apoptosis of peripheral blood mononuclear cells in children exposed to arsenic and fluoride. Environ Toxicol Pharmacol. 2011;32:399–405.

55. Luna AL, Acosta-Saavedra LC, Lopez-Carrillo L, et al. Arsenic alters monocyte superoxide anion and nitric oxide production in environmentally exposed children. Toxicol Appl Pharmacol. 2010;245:244–251.

56. Ahmed S, Mahabat-e Khoda S, Rekha RS, et al. Arsenic-associated oxidative stress, inflammation, and immune disruption in human placenta and cord blood. Environ Health Perspect. 2011;119:258–264.

57. Soto-Peña GA, Luna AL, Acosta-Saavedra L, et al. Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J. 2006;20:779–781.

58. Ahmed S, Ahsan KB, Kippler M, et al. In utero arsenic exposure is associated with impaired thymic function in newborns possibly via oxidative stress and apoptosis. Toxicol Sci. 2012;129:305–314.

59. Olsen CE, Liguori AE, Zong Y, Lantz RC, Burgess JL, Boitano S. Arsenic upregulates MMP-9 and inhibits wound repair in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2008;295:L293–L302.